Evaluating first-line immuno-oncology-based treatments for metastatic renal cell carcinoma in real world clinical practice using pre-treatment G8 scores

被引：0
|
作者：
Sazuka, Tomokazu [1 ]
Arai, Takayuki [1 ]
Sato, Hiroaki [1 ]
Goto, Yusuke [1 ]
Sakamoto, Shinichi [1 ]
Ichikawa, Tomohiko [1 ]
机构：
[1] Chiba Univ, Dept Urol, Grad Sch Med, Chiba, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2023年 / 30卷 / 11期
关键词：
D O I：
10.1111/iju.15249
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1054 / 1056
页数：3
相关论文
共 50 条
  • [41] Axitinib and avelumab (AA) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in the Northwest of England, United Kingdom.
    Allison, Jennifer
    Charnley, Natalie
    Stevenson, Robert
    Waddell, Tom
    Pillai, Manon Rhys
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [42] Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
    Shah, Neil J.
    Sura, Sneha
    Shinde, Reshma
    Shi, Junxin
    Perini, Rodolfo F.
    Puneet, Singhal
    Robert, Nicholas J.
    Vogelzang, Nicholas J.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [43] Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States (vol 8,e2400132,2024)
    Doshi, Gurjyot K.
    Osterland, Andrew J.
    Shi, Ping
    Yim, Annette
    Del Tejo, Viviana
    Guttenplan, Sarah B.
    Eiffert, Samantha
    Yin, Xin
    Rosenblatt, Lisa
    Conkling, Paul R.
    JCO CLINICAL CANCER INFORMATICS, 2025, 9
  • [44] Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group
    Savard, Marie-France
    Wells, J. Connor
    Graham, Jeffrey
    Dudani, Shaan
    Steinharter, John A.
    McGregor, Bradley A.
    Donskov, Frede
    Bjarnason, Georg A.
    Vaishampayan, Ulka N.
    Hansen, Aaron R.
    Iafolla, Marco A. J.
    Zanotti, Giovanni
    Huynh, Lynn
    Chang, Rose
    Duh, Mei S.
    Heng, Daniel Y. C.
    ONCOLOGIST, 2020, 25 (05): : 422 - 430
  • [45] Ipilimumab and nivolumab (I plus N) as first-line treatment of metastatic renal cell carcinoma (mRCC): A real-world review in North West of England, United Kingdom.
    Allison, Jennifer
    Griffiths, Richard
    Waddell, Tom
    Pillai, Manon Rhys
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [46] ESTIMATED COSTS FOR ALL-CAUSE GRADE 3/4 ADVERSE EVENTS AMONG FIRST-LINE TYROSINE KINASE INHIBITOR PLUS IMMUNO-ONCOLOGY-BASED COMBINATION THERAPIES FOR PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FROM THE UNITED STATES PERSPECTIVE
    Wallace, J. F.
    Adair, N.
    Perez, J. R.
    Hall, T.
    Bilen, M. A.
    Sussman, M.
    VALUE IN HEALTH, 2022, 25 (07) : S361 - S361
  • [47] THE COST-EFFECTIVENESS OF SEQUENTIAL FIRST- AND SECOND-LINE TREATMENTS IN METASTATIC RENAL CELL CARCINOMA USING REAL-WORLD DATA AND A PATIENT-LEVEL SIMULATION MODEL
    de Groot, S.
    Blommestein, H.
    Redekop, W.
    Oosterwijk, E.
    Kiemeney, L.
    Uyl-de Groot, C.
    VALUE IN HEALTH, 2013, 16 (07) : A587 - A587
  • [48] First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
    Roviello, Giandomenico
    Molina-Cerrillo, Javier
    Massari, Francesco
    Cerbone, Linda
    Fiala, Ondrej
    Fornarini, Giuseppe
    Monteiro, Fernando Sabino Marques
    Cattrini, Carlo
    Landmesser, Johannes
    Messina, Carlo
    Zgura, Anca
    Rebuzzi, Sara Elena
    Soares, Andrey
    Carrozza, Francesco
    Ansari, Jawaher
    Grillone, Francesco
    Kuronya, Zsofia
    Incorvaia, Lorena
    Bhuva, Dipen
    Ortega, Cinzia
    Nasso, Cecilia
    Kanesvaran, Ravindran
    Zampiva, Ilaria
    Porta, Camillo
    Buti, Sebastiano
    Santoni, Matteo
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (02)
  • [49] Real-world assessment of clinical outcomes among first-line (1 L) Sunitinib patients with metastatic renal cell carcinoma (MRCC) by the international Mrcc database consortium (IMDC) risk group
    Lynn Huynh
    Savard, Marie-France
    Wells, J. Connor
    Graham, Jeffrey
    Steinharter, John
    McGregor, Bradley
    Donskov, Frede
    Bjarnason, Georg A.
    Vaishampayan, Ulka
    Hansen, Aaron
    Iafolla, Marco
    Zanotti, Giovanni
    Nguyen, Catherine
    Chang, Rose
    Duh, Mei S.
    Heng, Daniel Y. C.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 124 - 125
  • [50] Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
    Du, Ella Xiaoyan
    Betts, Keith A.
    Wang, Travis
    Kitchen, Sophie A.
    He, Xuanhao
    Yin, Xin
    Guttenplan, Sarah B.
    Beauchamp, Karen
    Delgado, Andrew
    Rosenblatt, Lisa
    ONCOLOGY AND THERAPY, 2024, 12 (04) : 735 - 751
12345